REGISTERED NUMBER: 06070057 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 January 2026

for

Ryminster Medical Services Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTOR:

S G Charlesworth-Jones

REGISTERED OFFICE:

Charlesworth Court Knights Way

Battlefield Enterprise Park

Shrewsbury

Shropshire

SY1 3AB

REGISTERED NUMBER:

06070057 (England and Wales)

ACCOUNTANTS:

City, Chartered Accountants

Suite 540, 5th Floor,

Linen Hall

162- 168 Regent Street

London

W1B 5TF

FIXED ASSETS

Tangible assets

4

13,342

80,043

CURRENT ASSETS

Debtors

5

455,156

725,090

Cash at bank

433,796

344,993

888,952

1,070,083

CREDITORS

Amounts falling due within one year

6

(763,557

)

(1,023,659

)

NET CURRENT ASSETS

125,395

46,424

TOTAL ASSETS LESS CURRENT LIABILITIES

138,737

126,467

CREDITORS

Amounts falling due after more than one year

7

-

(3,925

)

PROVISIONS FOR LIABILITIES

(20,011

)

(20,011

)

NET ASSETS

118,726

102,531

CAPITAL AND RESERVES

Called up share capital

8

2

2

Share premium

106,350

-

Retained earnings

12,374

102,529

SHAREHOLDERS' FUNDS

118,726

102,531

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2026 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 27 July 2026 and were signed by:

S G Charlesworth-Jones - Director

1.	STATUTORY INFORMATION

Ryminster Medical Services Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Land and buildings

-

in accordance with the property

Plant and machinery etc

-

33% on cost and 20% on reducing balance

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Research and development

Research costs are expensed to the Profit and Loss account as incurred.

The Company capitalises development costs as intangible assets only if strict criteria are met (technical feasibility, intent to complete, ability to use or sell, future economic benefits, and resource availability). Costs failing these criteria are expensed.

Capitalised costs are amortised over their estimated useful life, usually [5-10] years, starting from commercial use.

Research and development tax credits

Credits or reliefs are recognised in the financial statements when there is reasonable assurance that the company will comply with the conditions attached to them and that the relief will be received. Tax credits are generally presented as a reduction to the tax charge in the Profit and Loss account.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 26 (2025 - 26 ) .

4.	TANGIBLE FIXED ASSETS

Plant and

Land and

machinery

buildings

etc

Totals

£

£

£

COST

At 1 February 2025

45,215

182,526

227,741

Additions

-

1,271

1,271

At 31 January 2026

45,215

183,797

229,012

DEPRECIATION

At 1 February 2025

27,129

120,569

147,698

Charge for year

9,043

58,929

67,972

At 31 January 2026

36,172

179,498

215,670

NET BOOK VALUE

At 31 January 2026

9,043

4,299

13,342

At 31 January 2025

18,086

61,957

80,043

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.1.26

31.1.25

£

£

Trade debtors

435,156

328,055

Amounts owed by group undertakings

-

397,035

Other debtors

20,000

-

455,156

725,090

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.1.26

31.1.25

£

£

Bank loans and overdrafts

6,869

12,837

Trade creditors

370,328

320,451

Taxation and social security

323,551

582,505

Other creditors

62,809

107,866

763,557

1,023,659

7.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

31.1.26

31.1.25

£

£

Bank loans

-

3,925

8.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.1.26

31.1.25

value:

£

£

50

Ordinary

£0.02

1

1

50

Ordinary A

£0.02

1

1

2

2

During the year a Special resolution was passed to subdivide the 1 current Ordinary and A Ordinary share with a nominal value of £1 each into 50 shares of £0.02 each.The rights of each class of shares remain unchanged.

During the year the following class of shares were issued at a premium;

Class

Nominal value

Number issued

Share capital

B Ordinary

£0.02

1

£0.02

C Ordinary

£0.02

1

£0.02

D Ordinary

£0.02

1

£0.02

E Ordinary

£0.02

1

£0.02

F Ordinary

£0.02

1

£0.02

The rights attached to the new shares are non-voting, non equity, having dividend rights and are non-redeemable.

The total consideration paid including the share premium amounted to £106,350.

9.	ULTIMATE CONTROLLING PARTY

The company is a wholly owned subsidiary and controlled by Ryminster Limited.